MINT-OLOPATADINE 0.2% DIN 02508605
Status: Marketed
Holder: MINT PHARMACEUTICALS INC
Molecule: OLOPATADINE (OLOPATADINE HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % |
|---|---|
| Dosage form | Solution |
| Route | Ophthalmic |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | S01GX09 OLOPATADINE |
| Original market date | 17-Dec-2021 |
| Current status date | 17-Dec-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mint Pharmaceuticals Inc — licence 101613, currently licensed, last inspection rating C (2023-01-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OLOPATADINE (OLOPATADINE HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02557495 | MED-OLOPATADINE | GENERIC MEDICAL PARTNERS INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Approved |
| 02422727 | MINT-OLOPATADINE | MINT PHARMACEUTICALS INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Marketed |
| 02521172 | OLOPATADINE | SANIS HEALTH INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Marketed |
| 02562375 | OLOPATADINE | STERI-MED PHARMA INC. | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Approved |
| 02541653 | OLOPATADINE 0.2% | SANIS HEALTH INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % | Marketed |
| 02456168 | OLOPATADINE OPHTHALMIC SOLUTION | BEXIMCO PHARMACEUTICALS CANADA LIMITED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Approved |
| 02362171 | PATADAY | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % | Marketed |
| 02233143 | PATANOL | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Marketed |
| 02458551 | PAZEO | NOVARTIS PHARMACEUTICALS CANADA INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.7 % | Marketed |
| 02358913 | SANDOZ OLOPATADINE | SANDOZ CANADA INCORPORATED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Marketed |
| 02420171 | SANDOZ OLOPATADINE 0.2% | SANDOZ CANADA INCORPORATED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % | Marketed |
| 02403986 | ACT OLOPATADINE 0.1% | TEVA CANADA LIMITED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Cancelled Post Market |
| 02404095 | ACT OLOPATADINE 0.2% | TEVA CANADA LIMITED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % | Cancelled Post Market |
| 02402823 | APO-OLOPATADINE | APOTEX INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.2 % | Dormant |
| 02305054 | APO-OLOPATADINE | APOTEX INC | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Dormant |
| 02458411 | JAMP-OLOPATADINE | JAMP PHARMA CORPORATION | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Dormant |
| 02312832 | TEVA-OLOPATADINE | TEVA CANADA LIMITED | Solution | OLOPATADINE (OLOPATADINE HYDROCHLORIDE) 0.1 % | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25346 | 2021-03-04 | Abbreviated New Drug Submission (ANDS) |